HSP90 inhibition: two-pronged exploitation of cancer dependencies.
about
Maximizing the Therapeutic Potential of HSP90 InhibitorsSteroid Receptor-Associated Immunophilins: A Gateway to Steroid SignallingCo-Crystalization and In Vitro Biological Characterization of 5-Aryl-4-(5-Substituted-2-4-Dihydroxyphenyl)-1,2,3-Thiadiazole Hsp90 InhibitorsHsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteinsDynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapyHSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cellsEffects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance SpectroscopyDevelopment of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.The spectral properties of (-)-epigallocatechin 3-O-gallate (EGCG) fluorescence in different solvents: dependence on solvent polarityThe heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function.Temporal Phosphoproteome Dynamics Induced by an ATP Synthase Inhibitor Citreoviridin.Heat Shock Protein Augmentation of Angelica gigas Nakai Root Hot Water Extract on Adipogenic Differentiation in Murine 3T3-L1 Preadipocytes.Resistance to HSP90 inhibition involving loss of MCL1 addiction.A-ring oxygenation modulates the chemistry and bioactivity of caged Garcinia xanthones.Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.Inhibition of Heat Shock Protein 90 Prevents HIV ReboundPotent antitrypanosomal activities of heat shock protein 90 inhibitors in vitro and in vivo.Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with TrastuzumabColorectal cancer cells display chaperone dependency for the unconventional prefoldin URI1.Recognition of enzymes lacking bound cofactor by protein quality control.Targeting the LKB1 tumor suppressor.Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.Discovery of small molecule cancer drugs: successes, challenges and opportunities.Helicobacter pylori: gastric cancer and extragastric malignancies - clinical aspects.Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2-amino-7-[4-fluoro-2-(3-pyridyl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one oxime.Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stressCombining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.D3R grand challenge 2015: Evaluation of protein-ligand pose and affinity predictions.The expanding proteome of the molecular chaperone HSP90.Geldanamycin-mediated inhibition of heat shock protein 90 partially activates dendritic cells, but interferes with their full maturation, accompanied by impaired upregulation of RelB.The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors.Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.PPARγ needs a helping hand to make fat.5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.Resorcinol-Based Grp94-Selective Inhibitors.Second Generation Grp94-Selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer.Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.
P2860
Q26798318-F944494F-610C-45F2-8C85-D60C3FC6D16BQ26801686-DB65F457-C6A6-40B7-B49A-C7ED7C9722D5Q27673253-D4AEC819-F230-4071-BDFE-EA3E96DEA7A1Q28485399-78DD03B0-97FB-4824-81CB-D6185D42181BQ28535465-7EAE086A-9747-4E09-8DB9-A154D6B8C830Q33823200-94E0D676-83FC-4FA9-BF62-DCDFD610B0F0Q34278997-3621E198-69D3-43B8-AD6D-E6662748284BQ35017614-E23E813D-D01C-43E9-BCA0-4D8969E97A2FQ35053298-65DB9374-16BB-434E-8718-774F15862459Q35164144-6C2C921A-CE8E-49D9-8B88-3FDF0ECA83F3Q36382137-2DAB8422-4325-4F61-9321-FDFF5B4F8471Q36604376-0DD57713-B5A9-4DEA-9022-37E0F00EFBDCQ36739850-B2B0CF26-8434-46C7-95A2-36F01D9B04A3Q36762412-C5009CA4-BAD6-4934-AF12-D9F2C682D9D4Q36846377-350D7E4B-BB89-4EC8-9E8B-6C779E177B1CQ36847206-F4D24EA9-CED9-4C7C-B05B-E0A6F9BDC3E2Q36876244-0480E2F6-6157-4798-925B-743409835E56Q36974927-99EF6E21-3507-42DF-B6A2-B04DDDACA60EQ37031569-4D4CD4C5-1B9B-407F-A30E-765D1FB1CE17Q37130692-2DF2A362-4479-45D7-96E9-56C11B66982BQ37148772-F20F49C8-D181-4890-BA59-6532EB1CEAACQ37301900-A4D6F5CE-6DDC-4EC7-A992-C9CC22187CEEQ37379804-CBE7E4FA-AE59-40E3-A4A6-13F06A6374ABQ37506032-C0124463-D871-4614-B174-C44510817971Q37705776-EB4C56BF-F7BE-40B7-B036-366125D7A6A8Q37996113-0A13A0C1-19A4-4592-83FB-1A3964DBF727Q38134872-8AA31BF2-0FC8-4696-A548-9803DC763FF5Q39002157-8E06EEB2-038B-408F-B1DA-6F0F724B996DQ39120344-0209588C-FE59-4974-B693-4CA05340DDF9Q39126075-BA7DA52C-0B57-4FCB-8264-A7222AF31ABFQ39328873-685E1D0E-9787-4CBC-B8BA-325F6D4E9BA5Q39640356-62D37D65-5641-494C-B524-6A5F3C72A6B6Q41959409-70366BE9-9CB3-4627-9E43-09E8EED2ED29Q42082409-B38352E3-CB19-4B4B-980F-EA41F7242F3FQ42770281-A5E4AA8A-F279-4F67-B360-806A76C830C5Q42810678-D6E4536B-F36C-412F-91D7-788311898938Q44586980-99BC7781-3EBB-411A-A504-F66E1D7132C1Q47619180-96EC03FB-7ABA-4753-9901-7461A3D2E339Q47878536-3880E0D8-D7D2-4C30-A7E2-82FE227D0580Q49415335-D4E9C684-B1BE-4525-8522-47D1AE8D5768
P2860
HSP90 inhibition: two-pronged exploitation of cancer dependencies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HSP90 inhibition: two-pronged exploitation of cancer dependencies.
@en
HSP90 inhibition: two-pronged exploitation of cancer dependencies.
@nl
type
label
HSP90 inhibition: two-pronged exploitation of cancer dependencies.
@en
HSP90 inhibition: two-pronged exploitation of cancer dependencies.
@nl
prefLabel
HSP90 inhibition: two-pronged exploitation of cancer dependencies.
@en
HSP90 inhibition: two-pronged exploitation of cancer dependencies.
@nl
P1433
P1476
HSP90 inhibition: two-pronged exploitation of cancer dependencies.
@en
P2093
Jon Travers
Swee Sharp
P304
P356
10.1016/J.DRUDIS.2011.12.021
P50
P577
2011-12-30T00:00:00Z